Quadruple Therapy With Elotuzumab + RVD in Newly Diagnosed MM: Phase IIa Study

June 2-6, 2017; Chicago, Illinois

Addition of elotuzumab to RVD associated with high level of overall response in newly diagnosed patients with MM but higher than expected toxicity.

Format: Microsoft PowerPoint (.ppt)

File Size: 662 KB

Released: June 7, 2017

Acknowledgements

Supported by educational grants by

AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Cookie Settings